CyA had increased graft survival by 25% at one year in the NITP. The new drug, however, has not affected the importance of HLA matching and pretransplant antibodies in conditioning graft outcome. A limited number of pretransplant blood transfusions seems advisable in CyA-treated patients.
|Number of pages||4|
|Issue number||SUPPL. 2|
|Publication status||Published - 1985|
ASJC Scopus subject areas